Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 122

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 122
---
, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma will include patients with relapsed / refractory (R/R) FL.

To support the Phase 1/2 trial and inclusion of FL patients, IFLI initially invested $3 million into new shares of Innate, issued through a capital increase reserved to IFLI at a price of €1.56 per share and representing 2.26% of the share capital of Innate at the time of issuance. IFLI may also invest up to an additional $4.9 million into new shares of Innate, depending on the completion of certain milestones, at a price to be determined at the time of such investments.

Antibody Drug Conjugates

a. Overview

To further our R& D program, the Company continues to develop different approaches for the treatment of cancer utilizing its antibody engineering capabilities to deliver novel assets, with its innovative ANKET® platform and continuing to explore Antibody Drug Conjugates (ADC) formats. The Company has a robust pipeline of additional preclinical product candidates. Its additional disclosed preclinical pipeline includes:

- IPH45 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4

- IPH43, an anti-MICA/B ADC.

b. Proprietary : IPH4502

1. Rationale

Nectin-4 is overexpressed in multiple solid tumors with high medical need, but is expressed at low levels in some epithelia, including the skin, bladder, breast duct, and placenta. Enfortumab vedotin (EV), a Nectin-4-targeting antibody-drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload, has been approved for the treatment of urothelial carcinoma (UC), which exhibits highest Nectin-4 expression. To treat cancers with lower levels of Nectin-4 and improve the balance between efficacy and safety, we developed IPH4502. IPH4502 delivers a cancer-killing drug, exatecan, with a drug-to-antibody ratio (DAR) of 8.

2. Preclinical data

The preclinical data on IPH4502, a next-generation ADC targeting Nectin